{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:10:21Z","timestamp":1788307821110,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-09749-4","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T18:15:53Z","timestamp":1724436953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patterns of fluoroquinolone utilization and resistance in a tertiary care hospital: a retrospective cross-sectional analysis study from a developing country"],"prefix":"10.1186","volume":"24","author":[{"given":"Banan M.","family":"Aiesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahd","family":"Zuhour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak Abu","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mays Haj","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adham","family":"Abutaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah W.","family":"Al-Jabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Sabateen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u2019ed H.","family":"Zyoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"9749_CR1","doi-asserted-by":"crossref","unstructured":"Bush NG, Diez-Santos I, Abbott LR, Maxwell A. Quinolones: mechanism, lethality and their contributions to Antibiotic Resistance. Molecules 2020, 25(23).","DOI":"10.3390\/molecules25235662"},{"issue":"10","key":"9749_CR2","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1039\/C9MD00120D","volume":"10","author":"TDM Pham","year":"2019","unstructured":"Pham TDM, Ziora ZM, Blaskovich MAT. Quinolone antibiotics. Medchemcomm. 2019;10(10):1719\u201339.","journal-title":"Medchemcomm"},{"issue":"4","key":"9749_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/molecules21040268","volume":"21","author":"A Naeem","year":"2016","unstructured":"Naeem A, Badshah SL, Muska M, Ahmad N, Khan K. The current case of quinolones: synthetic approaches and antibacterial activity. Molecules. 2016;21(4):268.","journal-title":"Molecules"},{"issue":"7","key":"9749_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.2215\/CJN.08140718","volume":"14","author":"RF Eyler","year":"2019","unstructured":"Eyler RF, Shvets K. Clinical pharmacology of antibiotics. Clin J Am Soc Nephrol. 2019;14(7):1080\u201390.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9749_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.11604\/pamj.2021.38.62.21626","volume":"38","author":"TG Tekalign","year":"2021","unstructured":"Tekalign TG, Shiferaw MS, Hailegiyorgis TT, Embiale YB, Abebe FA. Hospital-based ciprofloxacin use evaluation in Eastern Ethiopia: a retrospective assessment of clinical practice. Pan Afr Med J. 2021;38:62.","journal-title":"Pan Afr Med J"},{"key":"9749_CR6","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/IDR.S293080","volume":"14","author":"T Melaku","year":"2021","unstructured":"Melaku T, Gashaw M, Chelkeba L, Berhane M, Bekele S, Lemi G, Wakjira T, Tesfaw G, Mekonnen Z, Ali S, et al. Evaluation of adult outpatient antibiotics use at Jimma Medical Center (with defined daily doses for usage Metrics). Infect Drug Resist. 2021;14:1649\u201358.","journal-title":"Infect Drug Resist"},{"key":"9749_CR7","unstructured":"Andreassen V, Waagsb\u00f8 B, Blix HS. Ciprofloxacin usage at a local hospital. Tidsskr nor Laegeforen 2020, 140(14)."},{"issue":"1","key":"9749_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40267-019-00688-8","volume":"36","author":"RH Werida","year":"2019","unstructured":"Werida RH, El-Okaby AM, El-Khodary NM. Evaluation of levofloxacin utilization in intensive care units of tertiary care hospital: a retrospective observational study. Drugs Ther Perspect. 2019;36(1):33\u20139.","journal-title":"Drugs Ther Perspect"},{"key":"9749_CR9","doi-asserted-by":"crossref","unstructured":"Ojkic N, Lilja E, Direito S, Dawson A, Allen RJ, Waclaw B. A roadblock-and-kill mechanism of Action Model for the DNA-Targeting antibiotic ciprofloxacin. Antimicrob Agents Chemother 2020, 64(9).","DOI":"10.1128\/AAC.02487-19"},{"key":"9749_CR10","doi-asserted-by":"publisher","first-page":"113741","DOI":"10.1016\/j.ejmech.2021.113741","volume":"224","author":"Y Jia","year":"2021","unstructured":"Jia Y, Zhao L. The antibacterial activity of fluoroquinolone derivatives: an update (2018\u20132021). Eur J Med Chem. 2021;224:113741.","journal-title":"Eur J Med Chem"},{"issue":"5","key":"9749_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.18773\/austprescr.2021.035","volume":"44","author":"D Baggio","year":"2021","unstructured":"Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr. 2021;44(5):161\u20134.","journal-title":"Aust Prescr"},{"key":"9749_CR12","unstructured":"Podder V, Sadiq NM. Levofloxacin. In: StatPearls edn. Treasure Island (FL) ineligible companies. Disclosure: Nazia Sadiq declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC.; 2023."},{"issue":"2","key":"9749_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000535119","volume":"147","author":"T Hoffman","year":"2024","unstructured":"Hoffman T, Atamna A, Litchevsky V, Amitai I, Yahav D. Fluoroquinolone Prophylaxis during Conventional Chemotherapy or hematopoietic stem cell transplantation for Acute Leukemia - pros and cons. Acta Haematol. 2024;147(2):186\u201397.","journal-title":"Acta Haematol"},{"key":"9749_CR14","unstructured":"Thai T, Salisbury BH, Zito PM. Ciprofloxacin. In: StatPearls edn. Treasure Island (FL) ineligible companies. Disclosure: Blake Salisbury declares no relevant financial relationships with ineligible companies. Disclosure: Patrick Zito declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC.; 2024."},{"issue":"12 Suppl 2","key":"9749_CR15","doi-asserted-by":"publisher","first-page":"ii7","DOI":"10.1093\/jac\/dkab172","volume":"76","author":"R Bruyndonckx","year":"2021","unstructured":"Bruyndonckx R, Adriaenssens N, Versporten A, Hens N, Monnet DL, Molenberghs G, Goossens H, Weist K, Coenen S. Consumption of antibiotics in the community, European Union\/European Economic Area, 1997\u20132017. J Antimicrob Chemother. 2021;76(12 Suppl 2):ii7\u201313.","journal-title":"J Antimicrob Chemother"},{"key":"9749_CR16","doi-asserted-by":"crossref","unstructured":"Benk\u0151 R, Matuz M, Pet\u0151 Z, Weist K, Heuer O, Vlahovi\u0107-Pal\u010devski V, Monnet DL, Galistiani GF, Blix HS, So\u00f3s G et al. Trends in the hospital-sector consumption of the WHO AWaRe Reserve group antibiotics in EU\/EEA countries and the United Kingdom, 2010 to 2018. Euro Surveill 2022, 27(41).","DOI":"10.2807\/1560-7917.ES.2022.27.41.2101058"},{"key":"9749_CR17","doi-asserted-by":"publisher","first-page":"1067973","DOI":"10.3389\/fphar.2023.1067973","volume":"14","author":"D Sokolovi\u0107","year":"2023","unstructured":"Sokolovi\u0107 D, Drakul D, Vuji\u0107-Aleksi\u0107 V, Joksimovi\u0107 B, Mari\u0107 S, Ne\u017ei\u0107 L. Antibiotic consumption and antimicrobial resistance in the SARS-CoV-2 pandemic: a single-center experience. Front Pharmacol. 2023;14:1067973.","journal-title":"Front Pharmacol"},{"key":"9749_CR18","doi-asserted-by":"crossref","unstructured":"Friedli O, Gasser M, Cusini A, Fulchini R, Vuichard-Gysin D, Halder Tobler R, Wassilew N, Pl\u00fcss-Suard C, Kronenberg A. Impact of the COVID-19 pandemic on Inpatient Antibiotic Consumption in Switzerland. Antibiot (Basel) 2022, 11(6).","DOI":"10.3390\/antibiotics11060792"},{"issue":"10325","key":"9749_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Global burden of","year":"2022","unstructured":"Global burden of. Bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355.","journal-title":"Lancet"},{"issue":"2","key":"9749_CR20","first-page":"78","volume":"57","author":"PR Shankar","year":"2007","unstructured":"Shankar PR, Upadhyay DK, Mishra P, Subish P, Dubey AK, Saha AC. Fluoroquinolone utilization among inpatients in a teaching hospital in western Nepal. J Pak Med Assoc. 2007;57(2):78\u201382.","journal-title":"J Pak Med Assoc"},{"key":"9749_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1471-2334-13-245","volume":"13","author":"ZT Yang","year":"2013","unstructured":"Yang ZT, Zahar JR, M\u00e9cha\u00ef F, Postaire M, Blanot S, Balfagon-Viel S, Nassif X, Lortholary O. Current ciprofloxacin usage in children hospitalized in a referral hospital in Paris. BMC Infect Dis. 2013;13:245.","journal-title":"BMC Infect Dis"},{"key":"9749_CR22","first-page":"639","volume":"11","author":"WK Kabbara","year":"2015","unstructured":"Kabbara WK, Ramadan WH, Rahbany P, Al-Natour S. Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia. Ther Clin Risk Manag. 2015;11:639\u201347.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"9749_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40360-018-0274-6","volume":"19","author":"M Sisay","year":"2018","unstructured":"Sisay M, Weldegebreal F, Tesfa T, Ataro Z, Marami D, Mitiku H, Motbaynor B, Teklemariam Z. Resistance profile of clinically relevant bacterial isolates against fluoroquinolone in Ethiopia: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2018;19(1):86.","journal-title":"BMC Pharmacol Toxicol"},{"key":"9749_CR24","doi-asserted-by":"crossref","unstructured":"Worku F, Tewahido D. Retrospective Assessment of Antibiotics Prescribing at Public Primary Healthcare Facilities in Addis Ababa, Ethiopia. Interdiscip Perspect Infect Dis 2018, 2018:4323769.","DOI":"10.1155\/2018\/4323769"},{"key":"9749_CR25","doi-asserted-by":"crossref","unstructured":"Lynch JP 3rd, File TM Jr., Zhanel GG. Levofloxacin for the treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther. 2006;4(5):725\u201342.","DOI":"10.1586\/14787210.4.5.725"},{"issue":"1","key":"9749_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13756-023-01355-4","volume":"12","author":"S Shbaita","year":"2023","unstructured":"Shbaita S, Abatli S, Sweileh MW, Aiesh BM, Sabateen A, Salameh HT, AbuTaha A, Zyoud SH. Antibiotic resistance profiles and associated factors of Pseudomonas infections among patients admitted to large tertiary care hospital from a developing country. Antimicrob Resist Infect Control. 2023;12(1):149.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"8","key":"9749_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: a Beast of Burden that needs to be tamed? Oncologist. 2022;27(8):625\u201336.","journal-title":"Oncologist"},{"key":"9749_CR28","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.ctrv.2022.102427","volume":"109","author":"DW Blayney","year":"2022","unstructured":"Blayney DW, Schwartzberg L. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review. Cancer Treat Rev. 2022;109:102427.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"9749_CR29","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa044097","volume":"353","author":"G Bucaneve","year":"2005","unstructured":"Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D\u2019Antonio D, Buelli M, Nosari AM, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353(10):977\u201387.","journal-title":"N Engl J Med"},{"issue":"6","key":"9749_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3109\/23744235.2016.1143963","volume":"48","author":"H Hallb\u00f6\u00f6k","year":"2016","unstructured":"Hallb\u00f6\u00f6k H, Lidstr\u00f6m AK, Pauksens K. Ciprofloxacin prophylaxis delays initiation of broad-spectrum antibiotic therapy and reduces the overall use of antimicrobial agents during induction therapy for acute leukaemia: a single-centre study. Infect Dis (Lond). 2016;48(6):443\u20138.","journal-title":"Infect Dis (Lond)"},{"issue":"1","key":"9749_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jinf.2018.05.004","volume":"77","author":"WV Kern","year":"2018","unstructured":"Kern WV, Weber S, Dettenkofer M, Kaier K, Bertz H, Behnke M, Weisser M, G\u00f6tting T, Widmer AF, Theilacker C. Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014. J Infect. 2018;77(1):68\u201374.","journal-title":"J Infect"},{"issue":"1","key":"9749_CR32","first-page":"Cd004386","volume":"1","author":"A Gafter-Gvili","year":"2012","unstructured":"Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, Kremer LC, Leibovici L. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1(1):Cd004386.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"9749_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jinf.2014.02.013","volume":"69","author":"S Kimura","year":"2014","unstructured":"Kimura S, Akahoshi Y, Nakano H, Ugai T, Wada H, Yamasaki R, Ishihara Y, Kawamura K, Sakamoto K, Ashizawa M, et al. Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. J Infect. 2014;69(1):13\u201325.","journal-title":"J Infect"},{"issue":"1","key":"9749_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","volume":"76","author":"M Mikulska","year":"2018","unstructured":"Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, Ceppi M, Bruzzi P, Viscoli C. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76(1):20\u201337.","journal-title":"J Infect"},{"issue":"10","key":"9749_CR35","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1002\/cam4.2395","volume":"8","author":"G Egan","year":"2019","unstructured":"Egan G, Robinson PD, Martinez JPD, Alexander S, Ammann RA, Dupuis LL, Fisher BT, Lehrnbecher T, Phillips B, Cabral S, et al. Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: a systematic review of randomized trials. Cancer Med. 2019;8(10):4536\u201346.","journal-title":"Cancer Med"},{"issue":"1","key":"9749_CR36","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/16078454.2019.1589706","volume":"24","author":"W Owattanapanich","year":"2019","unstructured":"Owattanapanich W, Chayakulkeeree M. Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis. Hematology. 2019;24(1):362\u20138.","journal-title":"Hematology"},{"issue":"7","key":"9749_CR37","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/cid\/ciab404","volume":"73","author":"MJ Satlin","year":"2021","unstructured":"Satlin MJ, Chen L, Douglass C, Hovan M, Davidson E, Soave R, La Spina M, Gomez-Arteaga A, van Besien K, Mayer S, et al. Colonization with fluoroquinolone-resistant enterobacterales decreases the effectiveness of Fluoroquinolone Prophylaxis in hematopoietic cell transplant recipients. Clin Infect Dis. 2021;73(7):1257\u201365.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"9749_CR38","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/cid\/ciy363","volume":"67","author":"MJ Satlin","year":"2018","unstructured":"Satlin MJ, Chavda KD, Baker TM, Chen L, Shashkina E, Soave R, Small CB, Jacobs SE, Shore TB, van Besien K, et al. Colonization with levofloxacin-resistant extended-spectrum \u03b2-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2018;67(11):1720\u20138.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"9749_CR39","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/cid\/ciy825","volume":"68","author":"M Hakki","year":"2019","unstructured":"Hakki M, Humphries RM, Hemarajata P, Tallman GB, Shields RK, Mettus RT, Doi Y, Lewis JS. Fluoroquinolone Prophylaxis selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis. 2019;68(12):2045\u201352.","journal-title":"Clin Infect Dis"},{"key":"9749_CR40","unstructured":"Gudiol C, Albasanz-Puig A, Laporte-Amarg\u00f3s J, Pallar\u00e8s N, Mussetti A, Ruiz-Camps I, Puerta-Alcalde P, Abdala E, Oltolini C, Akova M et al. Clinical predictive model of Multidrug Resistance in Neutropenic Cancer patients with bloodstream infection due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 2020, 64(4)."},{"issue":"Suppl 1","key":"9749_CR41","doi-asserted-by":"publisher","first-page":"e14152","DOI":"10.1111\/tid.14152","volume":"25","author":"N Singh","year":"2023","unstructured":"Singh N, Thursky K, Maron G, Wolf J. Fluoroquinolone prophylaxis in patients with neutropenia at high risk of serious infections: exploring pros and cons. Transpl Infect Dis. 2023;25(Suppl 1):e14152.","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"9749_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1471-2334-13-245","volume":"13","author":"ZT Yang","year":"2013","unstructured":"Yang ZT, Zahar JR, Mechai F, Postaire M, Blanot S, Balfagon-Viel S, Nassif X, Lortholary O. Current ciprofloxacin usage in children hospitalized in a referral hospital in Paris. BMC Infect Dis. 2013;13(1):245.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"9749_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/1757177420971850","volume":"22","author":"JK Ackah","year":"2021","unstructured":"Ackah JK, Neal L, Marshall NR, Panahi P, Lloyd C, Rogers LJ. Antimicrobial prophylaxis in adult cardiac surgery in the United Kingdom and Republic of Ireland. J Infect Prev. 2021;22(2):83\u201390.","journal-title":"J Infect Prev"},{"issue":"3","key":"9749_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2146\/ajhp120568","volume":"70","author":"DW Bratzler","year":"2013","unstructured":"Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195\u2013283.","journal-title":"Am J Health Syst Pharm"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09749-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09749-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09749-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T23:56:33Z","timestamp":1732665393000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09749-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9749"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09749-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the <i>Institutional Review Boards (IRBs) of An-Najah National University<\/i>. The collected data were exclusively utilized for clinical research endeavors, ensuring confidentiality and nondisclosure for any other purpose. Patient identities were safeguarded through coding. As retrospective data were utilized, the <i>IRB of An-Najah National University<\/i> waived the need for informed consent. The authors ensured adherence to pertinent guidelines and regulations in conducting all methods.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"856"}}